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Apoptosis plays an important role during development and in the maintenance of multicellular organisms. Bcl-2 family members affect cell
death in either a positive or negative fashion. Although some redundancy exists between family members, expression of certain family
members is important during development in an organ-specific manner. The founding family member bcl-2 tends to be highly expressed in the
embryo and declines postnatally following differentiation and maturation. Altered expression of bcl-2, as well as other family members, has
been observed in disease states potentially affecting treatment modalities. Here we examine the distribution and role death repressors bcl-2, bcl-
xL and bcl-w as well as death effectors bax and bak play regulating apoptosis in a tissue-specific manner. Understanding the normal role of
these proteins during embryogenesis and in the mature organ will give us important insight into what goes awry in various disease states.
D 2003 Elsevier B.V. All rights reserved.Keywords: bcl-2; bcl-w; bcl-xL; bax; bakApoptosis plays an integral role during development and
in the maintenance of multicellular organisms through the
removal of damaged, aged or autoimmune cells. Aberrant
regulation of apoptosis at any time from embryogenesis to
adulthood can result in a variety of disease states from
follicular lymphoma to renal hypoplasia. The bcl-2 family
of proteins regulates apoptosis in a positive and negative
fashion (Table 1). The founding member, bcl-2 (B cell
leukemia/lymphoma-2), was discovered at the interchromo-
somal breakpoint of t(14;18) in follicular B cell lymphoma
[1]. Bcl-2 contains four conserved domains (BH1, BH2,
BH3, BH4) that can be found in other family members (see
Fig. 1). Here we will examine the distribution (summarized
in Table 2) and role several death repressors (bcl-2, bcl-
w and bcl-xL) and death effectors (bax and bak) play,
regulating apoptosis in a tissue-specific manner.1. Bcl-2
Bcl-2 is a novel proto-oncogene that inhibits apoptosis
rather than promoting proliferation. Bcl-2 is inserted into the
outer mitochondrial, endoplasmic reticulum and nuclear
membranes in an Ncyto-Cin orientation with the bulk of the0167-4889/$ - see front matter D 2003 Elsevier B.V. All rights reserved.
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E-mail address: cmsorenson@facstaff.wisc.edu (C.M. Sorenson).protein facing the cytosol [2]. Normally bcl-2 is located on
chromosome segment 18q21.3. It is a large gene containing
three exons, the first of which is not translated. Bcl-2
contains four conserved domains denoted BH1 (residues
136–155), BH2 (187–202), BH3 (93–107) and BH4 (10–
30) as well as a transmembrane spanning region at the
carboxy end of the protein [3]. Through the BH domains
formation of homo- and heterodimers with various bcl-2
family members impacts regulation of apoptosis. Deletion of
N-terminal amino acids 6–31, which includes the BH4
domain, imparts a dominant negative phenotype, causing
promotion of cell death [4]. Bcl-2 with the BH4 domain
deleted (amino acids 10–30) lacks the survival function but
has been shown to avidly binds to bax, bik/nbk, bak, bad, bid
and bim with a similar affinity as wild-type bcl-2 does [5].
Overexpression of bcl-2 increases the viability of cells
under various adverse circumstances including cytokine
withdrawal, loss of cell adhesion, as well as g-irradiation.
Bcl-2 expression can be regulated by interaction of integrins
with components of the basement membrane. For example,
overexpression of bcl-2 in epithelial cells promotes dedif-
ferentiation, a loss of expression of E-cadherin and a2h1
integrin and multilayer formation at high density [6]. Bcl-2
transcription is elevated in cells attached to fibronectin
through a5h1 or vitronectin through avh3 [7]. Regulation
of cell survival function by bcl-2 requires FAK, Shc and
activated Ras (through PI3-kinase/Akt pathway) [7]. Bcl-2
Table 1
Bcl-2 family members
Anti-apoptotic Pro-apoptotic
BH3 domain-only multi-domain
Bcl-2 Bid Bax
Bcl-xL Bad Bak
Bcl-w Bik/Nbk Bok/Mtd
Mcl1 Blk Bcl-xS
A1/Bfl1 Hrk
Boo/Diva Bim/Bod
Nr13 Bnip3
Nix
Noxa
Bcl-2 family members either inhibit (anti-apoptotic) or promote (pro-
apoptotic) apoptosis. Most of the anti-apoptotic bcl-2 family members have
all four conserved BH domains. In contrast, many of the pro-apoptotic
family members contain only the BH3 domain. Although some have other
BH domains besides the BH3 domain, none of the pro-apoptotic bcl-2
family members have the conserved BH4 domain.
Table 2
Expression of bcl-2 family members in the embryo and adult
bcl-2 bcl-xL bcl-w bax bak
Embryo
Lymph node + nd nd nd nd
Liver + +  + nd
Lung + nd nd nd nd
Heart nd + nd + nd
Kidney + + nd + +
Brain + + nd + +
Spleen + nd nd nd nd
Thymus + nd nd nd nd
Adult
Lymph node nd + nd + +
Liver  +  + +
Lung  nd nd + +
Heart  + + + +
Kidney + low + +/ + +
Brain + + + + +
Spleen nd + + + +
Thymus + nd + + +
nd = not determined.
The expression of bcl-2 family members in tissue is summarized for both
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expression of bcl-2 and its family members could potential-
ly influence the state of differentiation.
embryonic and adult expression. Although the expression of these proteins
has been relatively well characterized in the adult, substantially less is
known regarding expression in the embryo. References are as noted in the
text.2. Kidney
Bcl-2 is widely expressed during development and
becomes restricted upon maturation in many tissues. The
kidney demonstrates this quite well. During nephrogenesis,
apoptosis tends to be inversely correlated with bcl-2 expres-
sion [9]. Bcl-2 is highly expressed early in the embryonic
kidney and its level decreases significantly at later times
such that its expression is normally low in the postnatal
kidney [10]. In the developing kidney bcl-2 is expressed in
the ureteric bud [10] and in epithelial condensates of the
metanephric blastema [9]. However, bcl-2 is not expressed
in uninduced mesenchyme [9]. During differentiation of the
renal vesicle, the epithelium of the nascent glomerulus is
initially strongly positive, but upon maturation and vascu-
larization, staining becomes limited to the parietal layer of
the Bowman’s capsule. Initially, tubules are strongly posi-
tive for bcl-2, but upon maturation staining significantlyFig. 1. The domain structure of pro- and anti-apoptotic bcl-2 family members. Bcl-
found in other family members. Some of the family members also have a carboxdecreases. The collecting duct has faint staining for bcl-2
and the renal calyces are negative [9]. In the adult human,
expression is significantly lower but detected in the parietal
epithelium of the Bowman’s capsule, the distal convoluted
tubule loop of Henle, proximal tubules and papillary col-
lecting ducts [9]. Thus, the fine-tuned regulation of apopto-
sis plays an important role during development and
throughout the life of the animal.
Loss of bcl-2 dramatically affects kidney development.
Mice deficient in bcl-2 (bcl-2  / ) develop renal hypo-
plasia/cystic dysplasia. Kidneys in these mice undergo
fulminant apoptosis of the metanephric blastema during
early embryogenesis (E12) and the renal epithelial cells do
not complete terminal differentiation in the postnatal kidney
[8,11–15]. At postnatal day 20 (P20), gross cyst formation2 contains four conserved bcl-2 homology domains (BH1–4) which can be
y-terminal hydrophobic transmembrane domain (TM).
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kidneys from bcl-2  / mice display nuclear localization
of h-catenin, loss of apical brush border actin staining and
sustained phosphorylation of FAK, paxillin, Src and ERKs
[8,13–15]. Thus, loss of bcl-2 early during nephrogenesis
may affect the ability of these kidneys to differentiate/
mature, perhaps due to failure to receive the appropriate
signals, inability to form appropriate signaling complexes or
due to excessive loss of progenitor cells.3. Renal disease
Renal cystic disease involves the inability of renal epithe-
lial cells to reach a mature phenotype. Cystic renal epithelium
has characteristics similar to those of embryonic epithelium,
including enhanced apoptosis and proliferation compared to
normal adult tissue. Increased levels of apoptosis are ob-
served in autosomal dominant polycystic kidney disease
(ADPKD), autosomal recessive polycystic kidney disease
(ARPKD) and renal dysplasia [16]. In patients with ADPKD,
bcl-2 is expressed in cystic tubular epithelium with mem-
brane localization in hyperplastic tubules. Apoptosis is ob-
served in dysplastic kidneys in areas of undifferentiated cells
[16] where bcl-2 is not expressed. In contrast, bcl-2 andPax-2
expressed in dysplastic tubular epithelium are not down-
regulated postnatally [17]. Thus, hyperproliferation and cyst
formation in these dysplastic kidneys may be the result of
retaining an immature cell type, with bcl-2 maintaining cell
viability and Pax-2 providing a proliferative signal.
Renal cell carcinomas (RCC) including tubular-papillary,
sarcomatoid variants and oncocytomas are strongly positive
for bcl-2 [9,18]. Bcl-2 expression in renal cell carcinoma
could be a function of the cell type of the tumor, a response
to increased apoptosis or more likely the result of tubular
epithelial cells expressing markers of a less differentiated
cell type. More recently, increased expression of bcl-2 and/
or bcl-xL in RCC was linked to low levels of apoptosis in
these tumors which may present significant challenges for
treatment regimes [19].
Bcl-2 also plays an important role during tubular regen-
eration following ischemic injury. In this setting, the
replacement of tubular epithelium mimics nephrogenesis.
In the rat, acute ischemic injury is characterized by two
peaks of apoptosis. The first small peak (at 3 days) is
followed by a rapid decrease in the percentage of apoptotic
cells [20]. Bcl-2 expression remains elevated for 3 days and
then returns to normal levels. It is localized to the epithelia
of regenerating tubules in the outer medulla. Normally
absent from proximal tubules, bcl-2 is expressed in regen-
erating proximal tubules at this time [21]. Increased ex-
pression of bcl-2 during the initial recovery phase may
facilitate re-epithelization.
The role of bcl-2 family members in organogenesis and
homeostasis tends to be organ- and family member-specific.
During kidney development, bcl-2 plays an essential role asa mediator of opposing forces. This is further emphasized by
reversal of the bcl-2  / renal phenotype in the absence
of Bim, a BH3-only death effector [22].
Although the mechanism by which bcl-2 facilitates
kidney morphogenesis is not completely understood, the
data discussed above indicate that bcl-2 expression is
indicative of a less differentiated/embryonic state consistent
with many disease states including cystic kidney diseases,
renal dysplasia, RCC and ischemic repair. Thus, bcl-2 may
not merely act as an inhibitor of cell death, but in addition,
its interaction with intracellular proteins that modulate cell
adhesive mechanisms may be an integral part of its function
during development and repair.4. Lymphoid tissue
Bcl-2 is expressed in the thymus, lymph nodes and
spleen during development [23]. A correlation exists be-
tween the topographical distribution of bcl-2 and the func-
tional compartments of these tissues. In the earliest stages of
lymphoid maturation, bcl-2 is highly expressed in pro-B
cells and CD4CD8 thymocytes and is down-regulated at
the pre-B/IgM+IgD and CD4+CD8+ thymocytes. In mature
B and T cells, bcl-2 is up-regulated. In tonsils or lymph
nodes, bcl-2 expression is most intense in the primary
lymphoid follicles and mantle zones of the secondary
follicles which contain long-lived, recirculating lympho-
cytes (reviewed in Refs. [24,25]).
Bcl-2  / mice undergo involution of the spleen and
thymus. A number of these mice demonstrated increased
amounts of apoptosis in the thymus and in the white pulp of
the spleen as evident by the remarkable decrease of white
pulp over time. In the young animal, the histology of the
thymus and spleen was normal, with normal CD4/CD8 and
CD3 profiles. The spleen contained both mature B and T
lymphocytes, suggesting that maturation can proceed in the
absence of bcl-2 [26]. Thymocytes from weaning normal and
bcl-2  / mice had similar survival rates in cell culture.
Bcl-2  / thymocytes were more prone to apoptosis when
incubated with 1 mM dexamethasone or g-irradiated com-
pared to normal thymocytes [26]. Thus, bcl-2 plays a impor-
tant role as a modulator of encountered apoptotic signals.
Bcl-2 was discovered at the interchromosomal break-
point of t(14;18) in follicular B cell lymphoma [1]. Further
insight into the role bcl-2 plays during lymphocyte matura-
tion was achieved using gain of function B and T lympho-
cyte transgenic mice. Overexpression of bcl-2 in the B cell
compartment increases the number of mature resting B cells
which accumulate due to extended survival. Bcl-2 immu-
noglobin transgenic mice display prolonged B cell memory
responses, which with time progress to a high-grade malig-
nant lymphoma [24]. Overexpression of bcl-2 in immature
thymocytes inhibits apoptosis caused by glucocorticoid,
radiation and anti-CD3 antibody but does not affect negative
selection. Not surprisingly, studies of patients with diffuse
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increased expression of bcl-2 and a poor outcome/chemo-
resistance which was potentiated by bcl-x [27].5. Hair follicle
Hair follicle morphogenesis requires the intricately con-
trolled regulation of apoptosis, proliferation and differenti-
ation. Hair follicles are mini-organs that, during postnatal
life, cycle through periods of resting (telogen), active
growth (anagen) and apoptosis-driven involution (catagen)
(reviewed in Ref. [28]). Substantial amounts of apoptosis
occurs during hair follicle morphogenesis. Expression of
bcl-2 is strictly hair cycle-dependent with the dermal papilla
consistently expressing bcl-2 [29,30]. Other regions express
bcl-2 during certain portions of the hair cycle. Bcl-2 is
expressed in the hair follicle epithelium during early anagen
but bcl-2 is not expressed there during telogen. During
catagen, a gradient expression of bcl-2 is observed with
decreased amounts observed toward the distal hair follicle
epithelium. Thus, bcl-2 tends to be expressed more during
phases of intense proliferation and down-regulated during
hair follicle regression.
Mice deficient in bcl-2 display altered hair follicle
cycling. In normal postnatal mice, initiation of the first
anagen occurs at 4 weeks compared to bcl-2  / mice in
which the first anagen occurred at 5–6 weeks resulting in a
hypopigmented coat [26,31]. The hypopigmentation was
observed in a wavelike manner, first being observed at the
nose and proceeding toward the tail in both black and agouti
backgrounds. In C57BL/6 mice (‘‘black background’’),
anagen development starts at the rear and proceeds toward
the head while catagen development occurs in the opposite
direction [32]. Thus, in the bcl-2  / mice graying
appears in a catagen wave. The graying that occurs in these
mice is thought to be the result of melanocyte apoptosis
during the first catagen [33]. In contrast, overexpression of
bcl-2 in the epidermis and outer root sheath (with the keratin
14 promoter) leads to acceleration of the first anagen
development. When these mice are subjected to ultraviolet
B light, fewer apoptotic keratinocytes are observed. Inter-
estingly, when these mice are subjected to chemotherapy-
induced alopecia (cyclophosphamide) a promotion of folli-
cle dystrophy was observed [34]. Expression of bcl-2
ectopically in the suprabasal epidermal layers (keratin 1
promoter) results in multifocal hyperplasia without associ-
ated hyperkeratosis. Therefore, the role bcl-2 plays in hair
follicle cycling is complex and may depend on location and
state of differentiation.6. Nervous system
Bcl-2 is expressed in the embryonic and adult nervous
system. Its expression is highest during development withexpression in the ventricular zones and differentiating neu-
rons, particularly in the developing cortical plate. Postna-
tally bcl-2 is expressed in areas undergoing neurogenesis.
When neurogenesis is complete, bcl-2 expression declines
to very low levels. However, expression of bcl-2 in neurons
of the peripheral nervous system remains high in the adult
[35,36]. Loss of bcl-2 results in subtle abnormalities which
affect the maintenance of select neuronal subpopulations
during postnatal life [37]. Overexpression of bcl-2 decreases
neuronal cell death resulting in increased neuron number in
specific regions of the brain [38].
Apoptosis plays an important role in the adult brain.
Altered regulation of apoptosis is associated with neurode-
generative disorders. However, the role bcl-2 plays in these
disorders requires further investigation. Decreased expres-
sion of bcl-2 is observed in Alzheimer’s dementia in
neurons with neurofibrillary tangles [39,40] while others
observe increased expression of bcl-2 in the brain temporal
cortex in the membranous fraction [41]. In amyotrophic
lateral sclerosis mouse models, expression of bcl-2 can
delay onset and mortality [42,43]. Overexpressing of bcl-2
in transgenic mice protects neurons during ischemia [44].
Interestingly, in human glioma cells, bcl-2 promotes migra-
tion and invasiveness perhaps as a result of increased
activity of matrix metalloproteinase-2 (MMP-2) [45]. Thus,
bcl-2 may play more of a supportive role in the brain
perhaps by enhancing the function of other proteins.7. Angiogenesis
Angiogenesis is regulated by both positive and negative
control mechanisms. It plays an important role during
development, wound healing and during inflammation. In
many disease states the rigid control of capillary prolifera-
tion is lost, resulting in excessive angiogenesis. This is
accomplished by up-regulation of proangiogenic and/or
down-regulation of angiostatic factors.
Vascular endothelial growth factor (VEGF) has potent
angiogenic activity. It functions as an endothelial cell
mitogen and survival factor. VEGF up-regulates bcl-2
expression in endothelial cells as well as in VEGF receptor
positive primary leukemias and other tumor cells [46,47],
which may explain its ability to act as a survival factor. In
contrast, angiostatic factors generally inhibit angiogenesis
by promoting apoptosis of endothelial cells. Down-regula-
tion of bcl-2 may play a significant role in endothelial cell
apoptosis. Endometrial carcinomas show increased bcl-2
expression and angiogenesis [48]. Thus, bcl-2 may increase
the tumorigenicity and/or invasiveness of tumors by affect-
ing angiogenesis.
The normal role bcl-2 plays during vascular develop-
ment requires further study. In our recent studies with bcl-2
 / mice, we have observed that the retinal vascular
density is reduced significantly. In normal mice, postnatal
retina vasculature development is complete by 3 weeks,
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 / mice demonstrate decreased vasculature density by 3
weeks of age mainly due to reduced numbers of endothelial
cells and pericytes (Sorenson and Sheibani, unpublished
data). Expression of bcl-2 may also act as a protective
mechanism for endothelial cells under oxidative or mechan-
ical stress. Acute hydrostatic lung edema induces bcl-2
expression in arteriolar and venular endothelial cells in a
vascular pressure- and fluid filtration rate-dependent man-
ner. In these studies, endothelial cell apoptosis was ob-
served in alveolar capillaries where bcl-2 expression was
not induced during the time period examined [49]. How-
ever, whether these changes in bcl-2 expression and apo-
ptosis can contribute to chronic congestive heart failure
remains to be seen. Thus, bcl-2 may play an important role
in survival of vascular cells.8. Bcl-2 family members
8.1. Bcl- xL
Bcl-x was initially discovered in the chicken by low
stringency hybridization with a murine bcl-2 cDNA [50].
Two distinct forms of bcl-x are identified as bcl-xL (233
amino acids) and bcl-xS (170 amino acids: BH1 and BH2
deleted by alternative splicing). Bcl-xL inhibits cell death
while bcl-xS facilities it. Bcl-xL localizes to perinuclear
envelope and mitochondrial membranes [51]. Expression
studies demonstrate that bcl-xL is predominantly expressed
postnatally. Bcl-xL is five- to sixfold more abundant in the
adult kidney, brain, and thymus than bcl-2. It is also highly
expressed in the embryonic liver, a major site of embryonic
hematopoiesis [51].
Mice deficient in bcl-x (lacks both isoforms) die around
embryonic day 13. Bcl-x  / mice demonstrate apoptosis
of hematopoietic cells in the liver, shortened life-span of
immature lymphocytes and extensive apoptosis of the post-
mitotic immature neurons of the developing brain, spinal
cord and dorsal root ganglia [52]. These abnormalities are
consistent with the pattern of expression of bcl-x [52].
Deletion of bax in the bcl-x  / mice significantly
enhances neuron survival suggesting bax and bcl-xL interac-
tion regulates survival of immature neurons [53]. Consistent
with this thesis are data demonstrating the neuroprotective
effect of bcl-xL against ischemic brain injury [54].
The expression of bcl-xL compliments bcl-2 expression
during B- and T-cell development. Bcl-xL is expressed at
very low levels in pro-B cells, up-regulated in pre-B cells and
then down-regulated in immature as well as mature resting B
cells [55]. Bcl-xL expression is rapidly up-regulated by
activation with LPS, surface Ig or CD40 signaling [55]. In
contrast, bcl-2 expression is not affected by this type of
activation. Thus, bcl-2 and bcl-xL may play different roles in
B cell selection. During T-cell development, bcl-xL tends to
play a role in post activation survival. It is expressed at thedouble positive stage and lost when thymocytes mature to
single positive T cells [56].
8.2. Bcl-w
Bcl-w is a bcl-2 family member with cell death inhibitory
activity [57]. Similar to its closest relatives, bcl-w localizes
to the cytoplasmic membranes of the nuclear envelope,
mitochondria and possibly the endoplasmic reticulum [58].
Bcl-w is widely expressed particularly in the brain, spinal
cord, hematopoietic, fibroblasts, colon, testes, heart, pan-
creas, spleen and thymus [57,58]. No expression was
observed in liver, muscle or salivary gland. Bcl-w was
detected in mature B and T cells in lymph nodes, as well
as in granulocytes, monocytes and erythroid cells from bone
marrow [58].
Despite the wide spread expression of bcl-w, develop-
ment proceeds normally in its absence with one exception
[59,60]. Bcl-w-deficient males are sterile displaying pro-
gressive and nearly complete testicular degeneration. Sper-
matogenesis in the testis requires germ cell development
supported by Sertoli cells [61]. Bcl-w is expressed in Sertoli
cells but not in haploid germ cells. In bcl-w-deficient mice,
germ cell loss starts at weaning with near germ cell
depletion by 7 months. A similar loss of Sertoli cells was
observed and Leydig cells were also lost in these adult mice
[62]. These mice provide an interesting model to study how
loss of certain cell types affects spermatogenesis.
One potential role for bcl-w is the protection of adult
cells from apoptosis due to damage or stress. Bcl-w is
expressed in the intestine although its loss does not affect
normal development. When bcl-w  / mice are treated
with the cytotoxic drug 5-fluoruracil or with g-irradiation, a
sixfold increase in apoptosis in the intestine was noted [63].
Bcl-w is also widely expressed in the nervous system [64]
and is increased following ischemia [65] as well following
limbic seizures [66]. Therefore, although more studies are
needed in this area, the data available to date suggest that
developmental/spontaneous and damage-induced apoptosis
may be influenced in different manners by individual bcl-2
family members.
8.3. Bax
Bax, a pro-apoptotic bcl-2 family member, was identified
by co-immunoprecipitation with bcl-2 [67]. Bax is a 21-kDa
protein that can form heterodimers with bcl-2 and bcl-x
[67]. In the adult, bax has wide spread expression which is
particularly obvious in kidney, liver and pancreas which
contain little or no bcl-2 [68]. Furthermore, in some tissues a
reciprocal pattern of expression exists. In the lymph node,
bax expression is highest in the germinal center lympho-
cytes which have a high rate of apoptosis. In contrast, bcl-2
expression is highest in the mantle zone lymphocytes which
have a long-lived population of recirculating memory B
cells. Bcl-2 expression is absent in the most germinal center
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observed in the colon and small intestine. Therefore, the
expression patterns for bax in relationship to bcl-2 may
represent the distinct roles they play in the mature organ.
The unique roles of these family members are further
demonstrated in the kidney following ischemia. In the adult
kidney, bax is normally expressed in distal tubules and thick
ascending limb. Its expression is elevated early following
ischemia (3 days) when hyperproliferation is evident. Ex-
pression is observed in epithelial cells of regenerating
tubules within the outer medulla and remains pronounced
in regenerating proximal tubules and papillary proliferations
even after 7 days post-ischemia [21]. In contrast, bcl-2
expression occurs during the initial recovery phase follow-
ing ischemic injury. Thus, bcl-2 expression may facilitate re-
epithelization while bax expression, during the recovery
phase, may assist removal of hyperplastic epithelia such as
papillary proliferations.
Bax-deficient mice are viable postnatally, but display
selective hyperplasia of lymphoid tissue. These mice
exhibited increased numbers of thymocytes and enlarged
spleens with increased numbers of B-cells. However, the B-
and T- cells had a normal phenotype on maturation[69]. Bax
 / mice also have increased number of sympathetic and
motor neurons. When these sympathetic neurons are cul-
tured, they are resistant to cell death from trophic factor
deprivation.
The male bax  / mice are infertile. The testes of adult
mice are atrophic and there is no evidence of sperm in the
epididymis or vas deferens. Normally, bax is strongly
expressed in the epithelial cells lining the ductuli efferenti
and epididymis. The most pronounced expression is at the
luminal surface of these cells where resorption of dead
sperm cells occurs. No bax staining is observed in mature
sperm cells or spermatids [69]. In contrast to male fertility
issues, bax  / females display relatively normal repro-
ductive performance but do have an extended ovarian life-
span [70]. Thus, the bax  / as well as the bcl-w  /
mice may serve as useful model systems to study male
infertility.
8.4. Bak
Bak is a pro-apoptotic bcl-2 family member that is
closely related to bax. Bak is expressed in most organs in
the adult [71]. Interestingly, bak  / mice did not
demonstrate any developmental abnormalities [72]. The
bak  / mice were fertile, did not develop any age-
related abnormalities and isolated cells behaved normally
when induced to apoptose [72]. Thus, bak’s function may be
redundant.
Further insight into bak’s role has been achieved by
examining bax / bak / mice. Both bax and bak
are pro-apoptotic family members with widespread tissue
distribution and minimal phenotypes were observed in mice
deficient in the individual proteins. However, mice lackingboth bax and bak died postnatally with less than 10%
reaching adulthood. These mice displayed multiple neuro-
logical abnormalities (deafness, circling behavior), grossly
abnormal hematopoietic system (increased numbers of he-
matopoietic progenitors), females with imperforate vaginas,
interdigital webs retained, enlargement of spleen and lymph
nodes due to mature B and T cell accumulation [72,73].
These data further support the role of bax and bak as
redundant proteins, capable of carrying out the others
function.
Although the bak knockout mice did not have any
phenotype, this does not rule out the role of aberrant bak
expression contributing to a disease state. Coeliac disease is
characterized by enterocyte apoptosis and development of
lesions. Normally, bak is expressed in epithelia in a gradient
fashion with increased expression from the base to the tip of
the villus [71]. In contrast, coeliac disease samples demon-
strate intense uniform staining of the entire epithelial layer
with no change in expression levels for bax or bcl-2. Bak
expression in coeliac disease samples is consistent with the
increased numbers of apoptotic cells observed in these
areas.9. Summary
Bcl-2 family members tend to play specialized roles
during development. Although some family members can
substitution for one another, for example bax and bak,
others are essential for embryogenesis (bcl-xL). To date,
the expression pattern of bcl-2 has been examined in the
greatest detail. It tends to be highly expressed in the embryo
and declines postnatally following differentiation/matura-
tion. Unfortunately, the distribution/expression of most of
the family members has not been examined in a cohesive
fashion embryonically. Understanding the expression of
these proteins during embryogenesis and in the mature
organ is essential to truly comprehend their normal role in
the organ and determine what goes awry in various disease
states.
Aberrant expression of many of the bcl-2 family mem-
bers is observed in cancers, following ischemia, during
repair and in other disease states. In some cases, increased
expression of a particular family member correlates with a
good outcome and other times with a poor outcome. The
question then is whether the changes are a random occur-
rence, organ-, or disease-related. This is particularly impor-
tant when considering altering protein expression as a
treatment modality. A thorough understanding of the role(s)
these family members play during organogenesis is a
particularly useful tool since many disease states (some
cancers, repair following ischemia, etc.) have characteristics
similar to a less differentiated/embryonic state. One chal-
lenge is the treatment of hemopoietic and other malignan-
cies that are resistant to chemotherapeutic drugs. In B-cell
lymphoma and B-cell chronic lymphocytic leukemia, over-
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phenotype. Recent clinical trials have focused on the use of
a bcl-2 antisense oligonucleotide (G3139), complementary
to the first six codons, for use in combination with chemo-
therapuetic agents. Although G3139 down-regulated bcl-2
expression in melanoma, non-Hodkin’s lymphoma and
small cell lung carcinoma, the course of the disease did
not change significantly [74–76]. However, these trials
were only in phase I, and in the melanoma and non-
Hodgkin’s lymphoma studies, anti-tumor responses, both
complete and partial, were observed. Although bcl-2 plays
an important role during development, the fact that embryo-
genesis proceeds in its absence is an indicator of the
complexities of this family of proteins. Thus, the lack of a
positive treatment response with antisense bcl-2 may indi-
cate that a more complete understanding of the processes
reactivated in these disease states is required. Therefore, a
better understanding of the physiological function of bcl-2
family member gene products during development and in
the adult will be critical in harnessing their therapeutic
potential.Acknowledgements
C.M.S. would like to thank the PKD Foundation for
continued support. I would like to thank Drs. Aaron
Freidman, Nader Sheibani, Pam Kling and Julie Kessel for
critical comments on the manuscript. I would also like to
thank Kristin Repyak for table and reference assembly.References
[1] Y. Tsujimoto, C.M. Corce, Analysis of the structure, transcripts, and
protein products of bcl, the gene involved in human follicular lym-
phoma, Proc. Natl. Acad. Sci. 83 (1986) 5214–5218.
[2] M. Nguyen, D.G. Millar, V.W. Yong, S.J. Korsmeyer, G.C. Shore,
Targeting of bcl-2 to the mitochondrial outer membrane by a
COOH-terminal signal anchor sequence, J. Biol. Chem. 268 (1993)
25265–25268.
[3] R. Reed, H. Zha, C. Aime-Sempe, S. Takayama, H.G. Wang, Struc-
ture function analysis of bcl-2 family proteins, Mechanisms of Lym-
phocyte Activation and Immune Regulation VI, 1996, pp. 99–112.
[4] J.J. Hunter, B.L. Bond, T.G. Parslow, Functional dissection of the
human bcl-2 protein: sequence requirements for inhibition of apopto-
sis, Mol. Cell. Biol. 16 (1996) 877–883.
[5] D.C.S. Huang, J.M. Adams, S. Cory, The conserved N-terminal BH4
domain of Bcl-2 homologues is essential for inhibition of apoptosis
and interaction with CED-4, EMBO J. 17 (1998) 1029–1039.
[6] P.J. Lu, Q.L. Lu, A. Rughetti, J. Taylor-Papadimitriou, Bcl-2 over-
expression inhibits cell death and promotes the morphogenesis, but
not tumorigenesis of human mammary epithelial cells, J. Cell Biol.
129 (1995) 1363–1378.
[7] M. Matter, E. Ruoslahti, A signaling pathway from the a5h1 and avh3
integrins that elevates bcl-2 transcription, J. Biol. Chem. 276 (2001)
27757–27763.
[8] C.M. Sorenson, N. Sheibani, Focal adhesion kinase, paxillin and bcl-
2: analysis of expression. Phosphorylation and associatioin during
morphogenesis, Dev. Dyn. 215 (1999) 371–382.[9] D. Chandler, A.K. El-Naggar, S. Brisbay, R.W. Redline, T.J. McDon-
nell, Apoptosis and expression of the bcl-2 proto-oncogene in the fetal
and human adult kidney: evidence for the contribution of bcl-2 ex-
pression to renal carcinogenesis, Human Pathol. 25 (1994) 789–796.
[10] D.V. Novak, S.J. Korsmeyer, Bcl-2 protein expression during murine
development, Am. J. Pathol. 145 (1994) 61–73.
[11] C.M. Sorenson, S.A. Rogers, S.J. Korsmeyer, M.R. Hammerman,
Fulminant metanephric apoptosis and abnormal kidney development
in bcl-2-deficient mice, Am. J. Physiol. 268 (1995) F73–F81.
[12] C.M. Sorenson, B. Padanilam, M. Hammerman, Abnormal postpar-
tum renal development and cystogenesis in the bcl-2  / mouse,
Am. J. Physiol. 271 (1996) F184–F193.
[13] C.M. Sorenson, Nuclear localization of h-catenin and loss of apical
brush border actin in cystic tubules of bcl-2  / mice, Am. J.
Physiol. 276 (1999) F210–F217.
[14] C.M. Sorenson, N. Sheibani, Altered regulation of SHP-2 and PTP1B
tyrosine phosphatases in cystic kidneys from Bcl-2  / Mice, Am.
J. Physiol. 282 (2002) F442–F450.
[15] C.M. Sorenson, N. Sheibani, Sustained activation of MAPK/ERK’s
signaling pathway in cystic kidneys from bcl-2  / mice, Am. J.
Physiol. 283 (2002) F1085–F1090.
[16] P.J.D. Winyard, J. Nauta, D.S. Lirenman, P. Hardman, V.R. Sams,
R.A. Risdon, A.S. Woolf, Deregulation of cell survival in cystic
and dysplastic renal development, Kidney Int. 49 (1996) 135–146.
[17] P. Winyard, R.A. Risdon, V.R. Sams, G.R. Dressler, A.S. Woolf, The
PAX2 transcription factor is expressed in cystic and hyperproliferative
dysplastic epithelia in human kidney malformations, J. Clin. Invest.
98 (1996) 451–459.
[18] F. Paraf, J. Gogusev, Y. Chretien, D. Droz, Expression of bcl-2 onco-
protein in renal cell tumours, J. Pathol. 177 (1995) 247–252.
[19] G. Gobe, M. Rubin, G. Williams, I. Sawczuk, R. Buttyan, Apoptosis
and expression of bcl-2, bcl-XL, and bax in renal cell carcinomas,
Cancer Investig. 20 (2002) 324–332.
[20] A. Shimizu, N. Yamanaka, Apoptosis and cell desquamation in repair
process of ischemic tubular necrosis, Virchows Arch., B Cell. Pathol.
64 (1993) 171–180.
[21] D.P. Basile, H. Liapis, M.R. Hammerman, Expression of bcl-2 and
bax in regenerating rat renal tubules following ischemic injury, Am. J.
Physiol. 272 (1997) F640–F647.
[22] P. Bouillet, S. Cory, L. Zhang, A. Strasser, J. Adams, Degenerative
disorders caused by bcl-2 deficiency prevented by loss of its BH3-
only antagonist bim, Dev. Cell 1 (2001) 645–653.
[23] D. Lebrun, R. Warnke, M. Cleary, Expression of bcl-2 in fetal
tissues suggests a role in morphogenesis, Am. J. Pathol. 142
(1993) 743–752.
[24] G. Nunez, R. Merino, D. Grillot, M. Gonzalez-Garcia, Bcl-2 and
bcl-x: regulatory switches for lymphoid death and survival, Immu-
nol. Today 15 (1994) 582–587.
[25] M. Lopez-Hoyos, R. Carrio, J. Merino, R. Merion, Regulation of B
cell apoptosis by bcl-2 and bcl-XL and its role in the development of
autoimmune diseases, Int. J. Mol. Med. 1 (1998) 475–483.
[26] D.J. Veis, C.M. Sorenson, J.R. Shutter, S.J. Korsmeyer, Bcl-2-defi-
cient mice demonstrate fulminant lymphoid apoptosis, polycystic kid-
neys and hypopigmented hair, Cell 76 (1994) 777–779.
[27] O. Bairey, Y. Zimra, M. Shaklai, E. Okon, E. Rabizadeh, Bcl-2, bcl-X,
bax, and bak expression in short- and long-lived patients with diffuse
large B-cell lymphomas, Clin. Cancer Res. 5 (1999) 2860–2866.
[28] S. Muller-Rover, H. Rossiter, G. Lindner, E.M.J. Peters, T.S. Kupper,
R. Paus, Hair follicle apoptosis and bcl-2, J. Investig. Dermatol.
Symp. Proc. 4 (1999) 272–277.
[29] G. Lindner, V.A. Botchkarev, N.V. Botchkarev, G. Ling, C. van
der Veen, R. Paus, Analysis of apoptosis during murine hair fol-
licle regression (catagen), Am. J. Pathol. 151 (1997) 1601–1617.
[30] K.S. Stenn, L. Lawrence, D.J. Veis, S.J. Korsmeyer, M. Seiberg,
Expression of the bcl-2 proto-oncogene in the cycling adult mouse
hair follicle, J. Invest. Dermatol. 103 (1994) 107–111.
[31] S. Kamada, A. Shimono, Y. Shinto, T. Tsujimura, T. Takahashi, T.
C.M. Sorenson / Biochimica et Biophysica Acta 1644 (2004) 169–177176Noda, Y. Kitamura, H. Kondoh, Y. Tsujimoto, bcl-2 deficiency in
mice leads to pleiotropic abnormalities: accelerated lymphoid cell
death in thymus and spleen, Polycystic Kidney, Hair Hypopigmenta-
tion, and Distorted Small Intestine, Cancer Res. 55 (1995) 354–359.
[32] R. Paus, B. Handjiski, B.M. Czarnetzki, S. Eichmuller, A murine
model for inducing and manipulating hair follicle regression (cata-
gen): effects of dexamethasone and cyclosporin, Am. J. Invest. Der-
matol. 103 (1994) 143–147.
[33] D. Tobin, E. Hagen, V.A. Botchkarev, R. Paus, Do hair bulb mela-
nocytes undergo apoptosis during hair follicle regression (catagen)?
J. Invest. Dermatol. 111 (1998) 941–947.
[34] S. Muller-Rover, H. Rossiter, R. Paus, B. Handjiski, E.M.J. Peters,
J.-E. Murphy, L. Mecklenburg, T.S. Kupper, Overexpression of
bcl-2 protects from ultraviolet B-induced apoptosis but promotes
hair follicle regression and chemotherapy-induced alopecia, Am. J.
Pathol. 156 (2000) 1395–1405.
[35] D.E. Merry, D.J. Veis, W.F. Hickey, S.J. Korsmeyer, bcl-2 protein
expression is widespread in the developing nervous system and re-
tained in the adult CNS, Development 120 (1994) 301–311.
[36] M. Gonzalez-Garcia, I. Garcia, L. Ding, S. O’Shea, L.H. Boise, bcl-x
is expressed in embryonic and postnatal neural tissues and functions
to prevent neuronal cell death, Proc. Natl. Acad. Sci. U. S. A. 92
(1995) 4304–4308.
[37] T.M. Michaelidis, M. Sedtner, J.D. Cooper, et al., Inactivation of bcl-2
results in progressive degeneration of motoneurons, sympathetic and
sensory neurons during early post-natal development, Neuron 17
(1996) 75–89.
[38] J.-C. Martinou, M. Dubois-Dauphin, J.K. Staple, Overexpression of
Bcl-2 in transgenic mice protects neurons from naturally occurring
cell death and experimental ischemia, Neuron 13 (1994) 1017–1030.
[39] G.A. MacGibbon, P.A. Lawlor, M. Walton, E. Sirimanne, R.L. Faull,
B. Synek, E. Mee, B. Connor, M. Dragunow, Expression of fos, jun,
and krox family proteins in Alzheimer’s disease, Exp. Neurol. 147
(1997) 316–332.
[40] S. Vyas, Y. Javoy-Agid, M.T. Herrero, O. Strada, F. Boissiere, U.
Hibner, Y.J. Agid, Expression of bcl-2 in adult human brainn regions
with special reference to neurodegenerative disorders, J. Neurochem.
69 (1997) 223–231.
[41] Y. Kitamura, S. Shimohama, W. Kamoshima, T. Ota, Y. Matsuoka, Y.
Nomura, M.A. Smith, G. Perry, P.J. Whitehouse, T. Taniguchi, Alte-
ration of proteins regulating apoptosis, bcl-2, bcl-x, bax, bak, bad,
ICH-1 and CPP32, in Alzheimer’s disease, Brain Res. 780 (1998)
260–269.
[42] T. Ekegren, E. Grundstrom, D. Lindholm, S.M. Aquilonius, Upregu-
lation of bax protein and increased DNA degradation in ALS spinal
cord motor neurons, Acta Neurol. Scand. 100 (1999) 317–321.
[43] L.J. Martin, A.C. Price, A. Kaiser, A.Y. Shaikh, Z. Liu, Mechanisms
for neuronal degeneration in amyotrophic lateral sclerosis and in
models of motor neuron death, Int. J. Mol. Med. 5 (2000) 3–13.
[44] M.D. Linnik, P. Zahos, M.D. Geschwind, H.J. Federoff, Expression of
bcl-2 from a defective herpes simplex virus-1 vector limits neuronal
death in focal cerebral ischemia, Stroke 26 (1995) 1670–1675.
[45] W. Wick, S. Wagner, S. Kerkau, J. Dichgans, J. Tonn, M. Weller,
BCL-2 promotes migration and invasiveness of human glioma cells,
FEBS Lett. 440 (1998) 419–424.
[46] S. Dias, S.V. Shmelkov, G. Lam, S. Rafii, VEGF165 promotes sur-
vival of leukemic cells by Hsp90-mediated induction of bcl-2 expres-
sion and apoptosis inhibition, Blood 99 (2002) 2532–2540.
[47] J.E. Nor, J. Christensen, J. Liu, M. Peters, D.J. Mooney, R.M. Strieter,
P.J. Polverini, Up-regulation of bcl-2 in microvascular endothelial
cells enhances intratumoral angiogenesis and accelerates tumor
growth, Cancer Res. 61 (2001) 2183–2188.
[48] A. Mazurek, P. Pierzynski, W. Niklinska, L. Chyczewski, T. Laudan-
ski, Angiogenesis and Bcl-2 protein expression in patients with endo-
metrial carcinoma, Neoplasma 49 (2002) 149–154.
[49] N. Gotoh, K. Kambara, X.-W. Jiang, M. Ohno, S. Emura, T. Fujiwara,
H. Fujiwara, Apoptosis in microvascular endothelial cells of perfusedrabbit lungs with acute hydrostatic edema, J. Appl. Physiol. 88 (2000)
518–526.
[50] L.H. Boise, M. Gonzalez-Garcia, C.E. Postema, L. Ding, T. Lindsten,
L.A. Turka, X. Mao, G. Nunez, C.B. Thompson, Bcl-x, a bcl-2-re-
lated gene that functions as a dominant regulator of apoptotic cell
death, Cell 74 (1993) 597–608.
[51] M. Gonzalez-Garcia, R. Perez-Ballestero, L. Ding, L. Duan, L.H.
Boise, C.B. Thompson, G. Nunez, bcl-xl is the major bcl-x mRNA
form expressed during murine development and its product localizes
to mitochondria, Development 120 (1994) 3033–3042.
[52] N. Motoyama, F. Wang, K.A. Roth, H. Sawa, K.-I. Nakayama, K.
Nakayama, I. Negishi, S. Senju, Q. Zhang, S. Fujii, D.Y. Loh, Mas-
sive cell death of immature hematopoietic cells and neurons in bcl-x-
deficient mice, Science 267 (1995) 1506–1510.
[53] K.S. Shindler, C.B. Latham, K.A. Roth, Bax deficiency prevents
the increased cell death of immature neurons in bcl-x-deficient
mice, J. Neurosci. 17 (1997) 3112–3119.
[54] G. Cao, W. Pei, H. Ge, Q. Liang, Y. Luo, F.R. Sharp, A. Lu, S.H.
Graham, J. Chen, In vivo delivery of bcl-xl fusion protein con-
taining the TAT protein transduction domain protects against ische-
mic brain injury and neuronal apoptosis, J. Neurosci. 22 (2002)
5423–5431.
[55] D.A.M. Grillot, R. Merino, J.C. Pena, W.C. Fanslow, F.D. Finkelman,
C.B. Thompson, G. Nunez, Bcl-x exhibits regulated expression dur-
ing B cell development and activation and modulates lymphocyte
survival in transgenic mice, J. Exp. Med. 183 (1996) 381–391.
[56] E. Yang, S.J. Korsmeyer, Molecular thanatopsis: a discourse on the
Bcl-2 family and cell death, Blood 88 (1996) 386–401.
[57] L. Gibson, S.P. Holmgreen, D.C.S. Huang, O. Bernard, N.G. Cope-
land, N.A. Jenkins, G.R. Sutherland, E. Baker, J.M. Adams, S. Cory,
Bcl-w, a novel member of the bcl-2 family, promotes cell survival,
Oncogene 13 (1996) 575–665.
[58] L. O’Reilly, C. Print, G. Hausmann, K. Moriishi, S. Cory, D. Huang,
A. Strasser, Tissue expression and subcellular localization of the pro-
survival molecule bcl-w, Cell Death Differ. 8 (2001) 486–494.
[59] C.G. Print, K.L. Loveland, L. Gibson, T. Meehan, A. Stylianou, N.
Wreford, D. DeKretser, D. Metcalf, F. Kontgen, J. Adams, S. Cory,
Apoptosis regulator bcl-w is essential for spermatogenesis but appears
otherwise redundant, Proc. Natl. Acad. Sci. 95 (1998) 12424–12431.
[60] A.J. Ross, K.G. Waymire, J.E. Moss, A.F. Parlow, M.K. Skinner,
L.D. Russell, G.R. MacGregor, Testicular degeneration in bcl-w-de-
ficient mice, Nat. Genet. 18 (1998) 251–256.
[61] B. Capel, The battle of the sexes, Mech. Dev. 92 (2000) 89–103.
[62] L.D. Russell, J. Warren, L. Debeljuk, L.L. Richardson, P.L. Mahar,
K.G. Waymire, S.P. Amy, A.J. Ross, G.R. MacGregor, Spermatoge-
nesis in bcl-w-deficient mice, Biol. Reprod. 65 (2001) 318–332.
[63] D. Pritchard, C. Print, L. O’Reilly, J.M. Adams, C.S. Potten, J.A.
Hickman, Bcl-w is an important determinant of damage-induced
apoptosis in epithelia of small and large intestine, Oncogene 19
(2000) 3955–3959.
[64] S. Hamner, Y. Skoglosa, D. Lindholm, Differential expression of bcl-w
and bcl-x messenger RNA in the developing and adult rat nervous
system, Neuroscience 91 (1999) 673–684.
[65] M. Minami, K.L. Jin, W. Li, T. Nagayama, D.C. Henshall, R.P. Simon,
Bcl-w expression is increased in brain regions affected by focal cere-
bral ischemia in the rat, Neurosci. Lett. 279 (2000) 193–195.
[66] D.C. Henshall, S.L. Skradski, J.-Q. Lan, T. Ren, R.P. Simon, Increased
bcl-w expression following focally evoked limbic seizures in the rat,
Neurosci. Lett. 305 (2001) 153–156.
[67] Z.N. Oltvai, C.L. Milliman, S.J. Korsmeyer, Bcl-2 heterodimerizes In
Vivo with a conserved homolog, bax, that accelerates programmed
cell death, Cell 74 (1993) 609–619.
[68] S. Krajewski, M. Krajewski, A. Shabaik, T. Miyashita, H.G. Wang,
J.C. Reed, Immunohistochemical determination of In Vivo distribu-
tion of bax, a dominant inhibitor of bcl-2, Am. J. Pathol. 145 (1994)
1323–1336.
[69] C.M. Knudson, K.S.K. Tung, W.G. Tourtellotte, G.A.J. Brown, S.J.
C.M. Sorenson / Biochimica et Biophysica Acta 1644 (2004) 169–177 177Korsmeyer, Bax-Deficient mice with lymphoid hyperplasia and male
germ cell death, Science 270 (1995) 96–99.
[70] G.I. Perez, R. Robles, C.M. Knudson, J.A. Flaws, S.J. Korsmeyer,
J.L. Tilly, Prolongation of ovarian lifespan into advanced chronolog-
ical age by bax-deficiency, Nat. Genet. 21 (1999) 200–203.
[71] S. Krajewski, M. Krajewski, J. Reed, Immunohistochemical analysis
of in vivo patterns of bak expression, a proapoptotic member of the
bcl-2 protein family, Cancer Res. 56 (1996) 2849–2855.
[72] T. Lindsten, A.J. Ross, A. King, W. Zong, J.C. Rathmell, H.A. Shiels,
E. Ulrich, K.G. Waymire, P. Mahar, K. Frauwirth, Y. Chen, M. Wei,
V.M. Eng, D.M. Adelman, M.C. Simon, A. Ma, J.A. Golden, G.
Evan, S.J. Korsmeyer, G.R. MacGregor, C.B. Thompson, The com-
bined functions of proapoptotic bcl-2 family members bak and bax are
essential for normal development of multiple tissues, Mol. Cell 6
(2000) 1389–1399.
[73] J.C. Rathmell, T. Lindsten, W. X. Zong, R.M. Cinalli, C.B. Thomp-son, Deficiency in bak and bax perturbs thymic selection and lym-
phoid homeostasis, Nat. Immunol. 3 (10) (2002) 932–939.
[74] C.M. Rudin, G.A. Otterson, A.M. Mauer, M.A. Villalona-Calero, R.
Tomek, B. Prange, C.M. George, L. Szeto, E.E. Vokes, A pilot trial of
G3139, a bcl-2 antisense oligonucleotide, and paclitaxel in patients
with chemorefractory small-cell lung cancer, Ann. Oncol. 13 (2002)
539–545.
[75] J.S. Waters, A. Webb, D. Cunningham, P.A. Clarke, F. Raynaud, F.
di Stefano, F.E. Cotter, Phase I clinical and pharmacokinetic study
of bcl-2 antisense oligonucleotide therapy in patients with non-
Hodgkin’s lymphoma, J. Clin. Oncol. 18 (2000) 1812–1823.
[76] B. Jansen, V. Wacheck, E. Heere-Ress, H. Schlagbauer-Wadl, C.
Hoeller, T. Lucas, M. Hoermann, U. Hollenstein, K. Wolff, H. Pe-
hamberger, Chemosensitization of malignant melanoma by bcl-2
antisense therapy, The Lancet 356 (2000) 1728–1733.
